RGA study highlights potential of incretin-based therapies to improve global health outcomes
Reinsurance News - Nov 13, 2025
Reinsurance Group of America, Incorporated, a provider of life and health reinsurance solutions, has released new research that evaluates the potential effects of incretin-based therapies, including GLP-1 medications, on mortality and morbidity. These drugs, used for both weight management and diabe...
Recommended Articles
Posted: Mar 30, 2026
The conflict in the Middle East is causing commodity prices to soar, driven by disruptions to the su...
Posted: Mar 30, 2026
Howden Re, the global reinsurance, capital markets and strategic advisory arm of Howden Group, has a...
Posted: Mar 30, 2026
US-based insurer The Hartford has made several leadership updates within its international business...